Life Science Investing Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Life Science Investing Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Life Science Investing Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Life Science Investing Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Life Science Investing Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Life Science Investing Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology Congress 2025
pharmaceutical investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
Corvus Announces Presentation of Preclinical Data on CPI-818, a First-in-class Covalent Inhibitor of ITK Targeting T-Cell Lymphomas
Locksley Confirms Continuous High Grade Mineralized Silver Corridor at its Mojave Project in California
Homerun Resources Inc. Closes Acquisition of Additional Mineral Rights in the Santa Maria Eterna Silica Sand District
Rio Silver Highlights High-Grade Silver up to 6.26 g/t Au and 991 g/t Ag over 0.70 metres at Maria Norte and Advances a Clear Near-Term Development Path in Peru
NevGold Identifies Large Quantities of Previously Mined Material With Significant Antimony And Near-Term Production Potential In Historical Leach Pads at Limo Butte, Nevada
